Focus on Molecular Therapeutics
Below are all the Focus articles related specifically to our Molecular Therapeutics Research Program. All Focus articles are also available.
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.
January 07, 2013
March 26, 2012
April 15, 2010